3,164,501 Shares in Abivax SA Sponsored ADR $ABVX Bought by Darwin Global Management Ltd.

Darwin Global Management Ltd. purchased a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,164,501 shares of the company’s stock, valued at approximately $263,698,000. Abivax makes up about 7.3% of Darwin Global Management Ltd.’s portfolio, making the stock its 3rd biggest holding. Darwin Global Management Ltd. owned 4.07% of Abivax at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in shares of Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp acquired a new stake in Abivax in the 3rd quarter valued at about $36,000. Hantz Financial Services Inc. bought a new position in Abivax during the third quarter worth about $52,000. Gordian Capital Singapore Pte Ltd bought a new position in Abivax during the third quarter worth about $76,000. Finally, Covestor Ltd acquired a new position in Abivax during the third quarter worth approximately $96,000. Institutional investors own 47.91% of the company’s stock.

Abivax Trading Down 1.3%

Shares of NASDAQ:ABVX opened at $115.50 on Monday. Abivax SA Sponsored ADR has a 12-month low of $4.77 and a 12-month high of $148.83. The business has a 50 day moving average of $118.99 and a 200-day moving average of $109.10. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock has a market cap of $9.13 billion, a PE ratio of -27.63 and a beta of 1.01.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million during the quarter. As a group, equities research analysts forecast that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Citizens Jmp raised their price objective on Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 16th. Piper Sandler reissued an “overweight” rating and set a $142.00 target price on shares of Abivax in a report on Tuesday, December 16th. Oppenheimer set a $131.00 price target on Abivax in a research note on Thursday, January 8th. Wedbush initiated coverage on Abivax in a report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target for the company. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and an average price target of $134.75.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.